Product Code: GVR-4-68039-957-8
Cell Culture Media Market Growth & Trends:
The global cell culture media market size is expected to reach USD 10.70 billion by 2030, registering a CAGR of 12.54% from 2024 to 2030, according to a new report by Grand View Research, Inc. Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.
The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies. The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.
Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.
The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.
Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.
On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.
Cell Culture Media Market Report Highlights:
- By product, the serum-free media (SFM) segment held the highest market share of 36.0% in 2023. The use of serum-free media signifies a significant tool, which allows the researchers to perform specific applications or grow a specific cell type without using serum.
- The biopharmaceutical production segment dominated the market with a revenue share of 42.71% in 2023. Strategic activities by key biopharmaceutical companies, increasing R&D, demand for more reproducible and better-defined media and growing biosimilars market drives the segment growth
- By type, the liquid media segment captured the highest revenue share of 62.9% in 2023. This is attributed to increasing number of biopharmaceutical manufacturers, both downstream and upstream, are switching from premixed powders to liquid media and hence, propelling market growth
- By end-user, The pharmaceutical and biotechnology companies segment captured the highest revenue share of 34.25% in 2023, owing to the expansion of the current manufacturing capacities coupled with increasing prevalence of chronic disease which in turn demands for novel therapeutic drugs
- North America dominated the regional market with a revenue share of 37.58% in 2023 due to the growth in the pharmaceutical and biotechnology industry, presence of high R&D investment, and the development of novel culture media products in the region
- Asia Pacific is estimated to grow at the fastest CAGR of 14.92% during the forecast period owing to the increase in awareness associated with the use of the cell culture technique.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Information Procurement
- 1.3.1. Market Formulation & Data Visualization
- 1.3.2. Data Validation & Publishing
- 1.4. Research Assumptions
- 1.5. Research Methodology
- 1.5.1. Purchased Database
- 1.5.2. Gvr's Internal Database
- 1.5.3. 1secondary Sources
- 1.5.4. Primary Research
- 1.5.5. Details Of Primary Research
- 1.6. Information Or Data Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Validation
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis (Model 1)
- 1.8.1.1. Approach 1: Commodity Flow Approach
- 1.8.2. Volume Price Analysis (Model 2)
- 1.8.2.1. Approach 2: Volume Price Analysis
- 1.9. List Of Secondary Sources
- 1.10. Objectives
- 1.10.1. Objective 1:
- 1.10.2. Objective 2:
- 1.10.3. Market Estimation For Cell Culture Media Market
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Impact Analysis
- 3.3.1.1. Expansion Of Biosimilars And Biologics
- 3.3.1.2. Growth In Stem Cell Research
- 3.3.1.3. Emerging Cell Culture Technologies For Cell-Based Vaccines
- 3.3.2. Market Restraint Impact Analysis
- 3.3.2.1. Ethical Issues Concerning The Use Of Animal-Derived Products
- 3.3.2.2. Stringent Regulatory Guidelines
- 3.4. Business Environment Analysis
- 3.4.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.4.2. Porter's Five Forces Analysis
- 3.5. Recent Developments and Impact Analysis, by Key Market Participants
- 3.5.1. Mergers and acquisitions
- 3.5.2. Technological collaborations
- 3.5.3. Licensing and partnerships
- 3.6. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
- 4.1. Product Movement Analysis & Market Share, 2023 & 2030
- 4.2. Serum-free Media
- 4.2.1. Global serum-free media market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.2. CHO Media
- 4.2.2.1. Global CHO market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.3. HEK 293 Media
- 4.2.3.1. Global HEK 293 market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.4. BHK Media
- 4.2.4.1. Global BHK market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.5. Vero Medium
- 4.2.5.1. Global Vero Medium market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.6. Other serum-free media
- 4.2.6.1. Global other serum-free media market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3. Classical Media
- 4.3.1. Global Classical Media market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4. Stem Cell Culture Media
- 4.4.1. Global Stem Cell Culture Media Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 4.5. Chemically Defined Media
- 4.5.1. Global Chemically Defined Media Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 4.6. Specialty Media
- 4.6.1. Global Speciality Media Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 4.7. Other Cell Culture Media
- 4.7.1. Global Other Cell Culture Media Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Type Business Analysis
- 5.1. Type Movement Analysis & Market Share, 2023 & 2030
- 5.2. Liquid Media
- 5.2.1. Global Liquid Media Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.3. Semisolid & Solid Media
- 5.3.1. Global Semi-Solid & Solid Media Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Application Business Analysis
- 6.1. Application Movement Analysis & Market Share, 2023 & 2030
- 6.2. Biopharmaceutical Production
- 6.2.1. Global Biopharmaceutical Production Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.2.2. Monoclonal Antibodies
- 6.2.2.1. Global Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.2.3. Vaccines Production
- 6.2.3.1. Global Vaccines Production Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.2.4. Other Therapeutic Proteins
- 6.2.4.1. Global Other Therapeutic Proteins Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.3. Diagnostics
- 6.3.1. Global Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.4. Drug Screening & Development
- 6.4.1. Global Drug Screening & Development Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5. Tissue Engineering & Regenerative Medicine
- 6.5.1. Global Tissue Engineering & Regenerative Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Cell & Gene Therapy
- 6.5.2.1. Global Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Other Tissue Engineering & Regenerative Medicine
- 6.5.3.1. Global Other Tissue Engineering & Regenerative Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6. Other Applications
- 6.6.1. Global Other Applications Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7. End-User Business Analysis
- 7.1. Application Movement Analysis & Market Share, 2023 & 2030
- 7.2. Pharmaceutical & Biotechnology Companies
- 7.2.1. Global Pharmaceutical & Biotechnology Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3. Hospitals & Diagnostic Laboratories
- 7.3.1. Global Hospitals & Diagnostic Laboratories Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4. Research & Academic Institutes
- 7.4.1. Global Research & Academic Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5. Other End-User
- 7.5.1. Global Other End-User Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Cell Culture Media Market: Regional Estimates and Trend Analysis, by Product, Type, Application, & End-User
- 8.1. Cell Culture Media Market: Regional Outlook
- 8.2. North America
- 8.2.1. North America cell culture media market, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Competitive Scenario
- 8.2.2.3. Regulatory Framework
- 8.2.2.4. U.S. cell culture media market, 2018 - 2030 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Competitive Scenario
- 8.2.3.3. Regulatory Framework
- 8.2.3.4. Canada cell culture media market, 2018 - 2030 (USD Million)
- 8.3. Europe
- 8.3.1. Europe cell culture media market, 2018 - 2030 (USD Million)
- 8.3.2. UK
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Competitive Scenario
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. UK cell culture media market, 2018 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Competitive Scenario
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. Germany cell culture media market, 2018 - 2030 (USD Million)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Competitive Scenario
- 8.3.4.3. Regulatory Framework
- 8.3.4.4. France cell culture media market, 2018 - 2030 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Competitive Scenario
- 8.3.5.3. Regulatory Framework
- 8.3.5.4. Italy cell culture media market, 2018 - 2030 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Competitive Scenario
- 8.3.6.3. Regulatory Framework
- 8.3.6.4. Spain cell culture media market, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Competitive Scenario
- 8.3.7.3. Regulatory Framework
- 8.3.7.4. Denmark cell culture media market, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Competitive Scenario
- 8.3.8.3. Regulatory Framework
- 8.3.8.4. Sweden cell culture media market, 2018 - 2030 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Competitive Scenario
- 8.3.9.3. Regulatory Framework
- 8.3.9.4. Norway cell culture media market, 2018 - 2030 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific cell culture media market, 2018 - 2030 (USD Million)
- 8.4.2. Japan
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Japan cell culture media market, 2018 - 2030 (USD Million)
- 8.4.3. China
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. China cell culture media market, 2018 - 2030 (USD Million)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Competitive Scenario
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. India cell culture media market, 2018 - 2030 (USD Million)
- 8.4.5. Singapore
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Competitive Scenario
- 8.4.5.3. Regulatory Framework
- 8.4.5.4. Singapore cell culture media market, 2018 - 2030 (USD Million)
- 8.4.6. Australia
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Competitive Scenario
- 8.4.6.3. Regulatory Framework
- 8.4.6.4. Australia cell culture media market, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Competitive Scenario
- 8.4.7.3. Regulatory Framework
- 8.4.7.4. Thailand cell culture media market, 2018 - 2030 (USD Million)
- 8.4.8. South Korea
- 8.4.8.1. Key Country Dynamics
- 8.4.8.2. Competitive Scenario
- 8.4.8.3. Regulatory Framework
- 8.4.8.4. South Korea cell culture media market, 2018 - 2030 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America cell culture media market, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Brazil cell culture media market, 2018 - 2030 (USD Million)
- 8.5.3. Mexico
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Mexico cell culture media market, 2018 - 2030 (USD Million)
- 8.5.4. Argentina
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Competitive Scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Argentina cell culture media market, 2018 - 2030 (USD Million)
- 8.6. MEA
- 8.6.1. MEA cell culture media market, 2018 - 2030 (USD Million)
- 8.6.2. South Africa
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. South Africa cell culture media market, 2018 - 2030 (USD Million)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Saudi Arabia cell culture media market, 2018 - 2030 (USD Million)
- 8.6.4. UAE
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. UAE cell culture media market, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Kuwait cell culture media market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Position Analysis, 2023
- 9.4. Company Profiles/Listing
- 9.4.1. Sartorius AG
- 9.4.1.1. Overview
- 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. Danaher
- 9.4.2.1. Overview
- 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Merck KGaA
- 9.4.3.1. Overview
- 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. Thermo Fisher Scientific, Inc.
- 9.4.4.1. Overview
- 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. FUJIFILM Corporation
- 9.4.5.1. Overview
- 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. Lonza
- 9.4.6.1. Overview
- 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. BD
- 9.4.7.1. Overview
- 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. STEMCELL Technologies
- 9.4.8.1. Overview
- 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. Cell Biologics, Inc.
- 9.4.9.1. Overview
- 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. PromoCell GmbH
- 9.4.10.1. Overview
- 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Strategic Initiatives